Assessment of Finerenone Safety and Efficacy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.

Year : | Volume : 01 | Issue : | Page : –

    Roshni Gat


In this study, we present compelling evidence that supports the safety and effectiveness of finerenone in individuals diagnosed with type 2 diabetes and chronic renal disease. Our research is dedicated to improving the overall well-being of patients by enhancing their quality of life.
Finerenone exhibited a significant decrease in the likelihood of renal and cardiovascular (CV) events in individuals with both type 2 diabetes and chronic kidney disease. This exploratory subgroup analysis aims to investigate the potential influence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the therapeutic efficacy of finerenone.
Material and Method:-
A systemic review was undertaken, during which we scrutinized 5340 cases of these patients.
Among the 5340 patients examined, 394 individuals (6.9%) received GLP-1RAs. Regardless of baseline GLP-1RA use, finerenone was associated with a lower UACR, reflected in a ratio of least-squares means of 0.69. The analysis revealed a hazard ratio of 0.67 (95% confidence interval 0.67, 0.72) for patients without GLP-1RA use and 0.63 (95% confidence interval 0.56, 0.70) for those with GLP-1RA use (p value for interaction > 0.20). Importantly, the presence of At baseline, the p values for interaction (> 0.15 and > 0.51, respectively) indicate that the presence of GLP-1RA did not have a significant impact on finerenone’s effectiveness in reducing primary kidney outcomes (defined as time to kidney failure, sustained decrease in estimated glomerular filtration rate ≥40% from baseline, or renal death) or key secondary cardiovascular outcomes (including time to cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) compared to the placebo.

Keywords: Finerenone, Type 2 Diabetes , Chronic kidney Disease,Glomerular filtration, Cardiovascular outcomes, GLP-1 receptor agonists

How to cite this article: Roshni Gat Assessment of Finerenone Safety and Efficacy in Individuals with Type 2 Diabetes and Chronic Kidney Disease. ijab ; :-
How to cite this URL: Roshni Gat Assessment of Finerenone Safety and Efficacy in Individuals with Type 2 Diabetes and Chronic Kidney Disease. ijab {cited };:-. Available from:

var fieldValue = “[user_role]”;
if (fieldValue == ‘indexingbodies’) {
document.write(‘Full Text PDF‘);
else if (fieldValue == ‘administrator’) { document.write(‘Full Text PDF‘); }
else if (fieldValue == ‘ijab’) { document.write(‘Full Text PDF‘); }
else { document.write(‘ ‘); }


Muskiet MH, Wheeler DC, Heerspink HJ. New pharmacological strategies for protecting kidney function in type 2 diabetes. The Lancet Diabetes & Endocrinology. 2019 May 1;7(5):397-412
Sloan LA. Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of diabetes. 2019 Dec;11(12):938-48.
Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nature Reviews Nephrology. 2016 Feb;12(2):73-81
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FR. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PloS one. 2016 Jul 6;11(7):e0158765.
Ingelfinger JR, Rosen CJ. Finerenone – Halting Relative Hyperaldosteronism in Chronic Kidney Disease. N Engl J Med 2020;383:2285-6.
Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes2010;17:199-204
Yamazaki T, Mimura I, Tanaka T, Nangaku M: Treatment of diabetic kidney disease: current and future . Diabetes Metab J. 2021, 45:11-26. 10.4093/dmj.2020.0217
Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F: Mineralocorticoid receptor antagonists in diabetic kidney disease – mechanistic and therapeutic effects. Nat Rev Nephrol. 2022, 18:56-70. 10.1038/s41581-021 00490-8
Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302–8.
Li H, Lu W, Wang A, et al. Changing epidemiology of chronic kidney Disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J Diabetes Investig2021;12:346–56.
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novelNon-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in Patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453–63.

Subscription Review Article
Received January 12, 2024
Accepted January 24, 2024

function myFunction2() {
var x = document.getElementById(“browsefigure”);
if ( === “block”) { = “none”;
else { = “Block”; }
document.querySelector(“.prevBtn”).addEventListener(“click”, () => {
document.querySelector(“.nextBtn”).addEventListener(“click”, () => {
var slideIndex = 1;
function changeSlides(n) {
showSlides((slideIndex += n));
function currentSlide(n) {
showSlides((slideIndex = n));
function showSlides(n) {
var i;
var slides = document.getElementsByClassName(“Slide”);
var dots = document.getElementsByClassName(“Navdot”);
if (n > slides.length) { slideIndex = 1; }
if (n ( = “none”));
item => (item.className = item.className.replace(” selected”, “”))
slides[slideIndex – 1].style.display = “block”;
dots[slideIndex – 1].className += ” selected”;